You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Release

Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017

<< Back
02.23.17

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host a live webcast of its R&D Day on Thursday, March 9, 2017 beginning at 9:00 a.m. Eastern Time. Members of the Ironwood leadership team and external opinion leaders will provide R&D and commercial insights into key Ironwood product opportunities. The event is being held at Ironwood’s offices in Cambridge, MA.

The event will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 75432701.

The webcast will be available for replay via telephone starting March 9, 2017 at approximately 2:00 p.m. Eastern Time, running through 3:00 p.m. Eastern Time on March 16, 2016. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 75432701. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the webcast has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

Source: Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.
Media Relations
Trista Morrison, 617-374-5095
Director, Corporate Communications
tmorrison@ironwoodpharma.com
or
Investor Relations
Meredith Kaya, 617-374-5082
Director, Investor Relations
mkaya@ironwoodpharma.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Ironwood Pharmaceuticals's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.
Media contact
Trista Morrison
617.374.5095
tmorrison@ironwoodpharma.com

INVESTOR RELATIONS CONTACT
Meredith Kaya
617-374-5082
mkaya@ironwoodpharma.com